Asahi Kasei Pharma Corporation

We believe great science comes from working together.

Asahi Kasei Pharma Corporation is focused on the discovery and development of new drugs that address unmet medical needs.

October 7, 2021: Asahi Kasei Pharma to solicit proposals for drug discovery research
September 30, 2021: Asahi Kasei Pharma obtains exclusive option for AGN1 LOEP Hip Kit
July 19, 2021: Sanofi and Asahi Kasei Pharma execute a marketing license agreement to transfer sales right in Japan for Plaquenil® Tablets 200 mg, an immunomodulator
January 29, 2021: Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate
October 13, 2020: Asahi Kasei Pharma to solicit proposals for drug discovery research
June 2, 2020: Asahi Kasei Pharma obtains Chinese approval for Flivas™ (naftopidil) dysuria treatment
March 19, 2020: Asahi Kasei Pharma concludes license agreement with SBI Biotech for SBI-3150
January 9, 2020: Denial of motion for preliminary injunction requesting continuous supply of XIAFLEX® injection

Page Top